Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 3,000 Shares

August 8, 2026 by InsiderTrades.com

Key Points

Insider sale: Zhenyu Xu sold 17,000 SOPHiA GENETICS shares for approximately $123,930 at an average price of $7.29 under a pre-arranged Rule 10b5-1 plan. Xu still directly owns 590,887 shares, and the transaction reduced the holding by 2.8%.
Mixed financial performance: The company reported quarterly revenue of $23.31 million, above estimates, but its loss of $0.26 per share was worse than the expected $0.21 loss. Analysts project a full-year loss of $0.77 per share, underscoring continued profitability challenges.
Analyst outlook remains mixed: BTIG and HC Wainwright raised their price targets to $9 and $14, respectively, while Weiss Ratings maintained a sell rating. The overall analyst consensus is Hold, with an average target price of $10.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 3,000 shares of the business's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $7.00, for a total value of $21,000.00. Following the completion of the sale, the insider owned 600,887 shares in the company, valued at $4,206,209. This represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.29, for a total value of $123,930.00.
On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.
On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $22,800.00.
On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.

SOPHiA GENETICS Trading Up 15.2%

SOPH stock opened at $7.71 on Friday. The firm has a fifty day moving average price of $5.63 and a 200 day moving average price of $5.15. SOPHiA GENETICS SA has a fifty-two week low of $2.96 and a fifty-two week high of $7.86. The firm has a market cap of $646.79 million, a PE ratio of -6.70 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.90 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. Sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. HC Wainwright lifted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.00.

View Our Latest Research Report on SOPH

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. purchased a new position in SOPHiA GENETICS during the 2nd quarter valued at $567,000. Royal Bank of Canada increased its stake in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares during the period. Sei Investments Co. bought a new stake in shares of SOPHiA GENETICS during the first quarter worth $1,772,000. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock worth $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the first quarter valued at $2,157,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.